Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099239 · ClinicalTrials.gov registry record · Phase 1
hCT-MSCs for Children With Autism Spectrum Disorder (ASD)
A Phase 1 study, sponsored by Joanne Kurtzberg, MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03099239 is a Phase 1 study that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 12 participants.
The verdict
NCT03099239, a Phase 1 study, has completed, sponsored by Joanne Kurtzberg, MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
The purpose of this Phase 1 study is to determine the safety of one, two, and three intravenous infusions of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC), administered every two months, in children with autism spectrum disorder (ASD).
Interventions
- BIOLOGICAL hCT-MSC infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-06-06 |
| Est. Completion | 2019-06-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099239
The ClinicalTrials.gov registry entry for NCT03099239 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joanne Kurtzberg, MD, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hCT-MSC infusion is the first listed.
NCT03099239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03099239 about?
NCT03099239 is a clinical study titled "hCT-MSCs for Children With Autism Spectrum Disorder (ASD)". The purpose of this Phase 1 study is to determine the safety of one, two, and three intravenous infusions of human umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC), administered every two months, in children with autism spectrum disorder (ASD).
What is the current status of trial NCT03099239?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-06-06. Estimated completion is 2019-06-10.
What interventions are being tested in trial NCT03099239?
The interventions under investigation include: hCT-MSC infusion (BIOLOGICAL).
Who is sponsoring clinical trial NCT03099239?
This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.